

CURRICULUM VITAE

Yu-Mei Cecilia Tan, MS, MBA, Ph.D.

EDUCATION

Doctor of Philosophy in Environmental Sciences and Engineering	2001
The University of North Carolina at Chapel Hill, Chapel Hill, NC	
Master of Business Administration in BioSciences & Financial Management	2009
North Carolina State University, Raleigh, NC	
Master of Science in Environmental Health Sciences	1997
Harvard School of Public Health, Boston, MA	
Bachelor of Science in Environmental Engineering	1995
National Cheng Kung University, Taiwan	

BRIEF CHRONOLOGY OF EMPLOYMENT

I have experience and expertise in both conducting scientific research and assessing human health risks, with a deep understanding of the methods and principles involved in both areas.

U.S. Environmental Protection Agency, Research Triangle Park, NC 2009 – present

Senior Science Advisor, Office of Pesticide Program 2018 – present

- *Support risk assessment using computational modeling and kinetic data*

Research Physical Scientist, Office of Pesticide Program (detail) 2016 – 2017

- *Conducted risk assessment using computational models for carbamates, organophosphates, pyrethroids, and triazines*

Research Physical Scientist, National Exposure Research Laboratory

- *Lead of the Biomonitoring Research team* 2010 – 2012
- *Project Planning Lead in Biomarker Research* 2011
- *Project Lead in Biomarker Research* 2011 – 2014
- *Acting Branch Chief* 2012
- *Task Lead in Pharmacokinetics Research* 2014 - 2018

The Hamner Institutes for Health Sciences, Research Triangle Park, NC 2001 – 2009
Associate Director, Center for Human Health Assessment 2005 – 2009
Research Investigator, Division of Computational Biology 2003 – 2009
Post-doctoral Fellow, Division of Computational Biology 2001 – 2003

The University of North Carolina at Chapel Hill, Chapel Hill, NC 1997 – 2001
The National Institute for Occupational Safety and Health (NIOSH) Trainee

Massachusetts Institute of Technology, Cambridge, MA 1996 – 1997
Industrial Hygienist, Environmental Health and Safety Office

RESEARCH INTERESTS

Physiologically based pharmacokinetic (PBPK) modeling	Classical pharmacokinetic modeling
Biologically based dose-response modeling	Exposure modeling
Adverse Outcome Pathway	Aggregate Exposure Pathway
Uncertainty and variability analysis	Biomonitoring
Human health risk assessment	Cheminformatics

WORKSHOPS AND COURSES

I leverage my leadership abilities and extensive knowledge and experience in physiologically based pharmacokinetic (PBPK) modeling by actively guiding and instructing others in their learning and development through organizing and teaching workshops and courses.

1. Organized and lectured a course on “Physiologically Based Pharmacokinetic (PBPK) Modeling and Risk Assessment”. CIIT Centers for Health Research, Research Triangle Park, NC, 26-30 September, 2005.
2. Organized and lectured a course on “Physiologically Based Pharmacokinetic (PBPK) Modeling and Risk Assessment”. CIIT Centers for Health Research, Research Triangle Park, NC, 6-10 February, 2006.

3. Organized and lectured a course on "Interpretation of Biomonitoring Data Using Physiologically Based Pharmacokinetic (PBPK) Modeling". CIIT Centers for Health Research, Research Triangle Park, NC, 25-29 September, 2006.
4. Organized and lectured a course on "Interpretation of Biomonitoring Data Using Physiologically Based Pharmacokinetic (PBPK) Modeling". 2007 Joint ISEA/ISEE Annual Meeting, Durham, NC, 14 October, 2007.
5. Organized and lectured a course on "Physiologically Based Pharmacokinetic (PBPK) Modeling and Risk Assessment". The Hamner Institutes for Health Research, Research Triangle Park, NC, 11-15 February, 2008.
6. Lectured at a course on 2009 Society of Toxicology Annual Meeting Continuing Education Course – Characterizing variability and uncertainty with physiologically based pharmacokinetic models. "Variability in exposure and internal dosimetry assessed with PBPK models". Baltimore, MD, 15 March, 2009.
7. Organized and lectured a course on "Physiologically Based Pharmacokinetic (PBPK) Modeling in Drug Development and Evaluation". Alexandria, VA, 6-10 April, 2009.
8. Organized and Chaired a Workshop "Considering pharmacokinetics as the mechanistic basis to link chemical exposures to adverse outcome pathways" at the 2015 Society of Toxicology Annual Meeting, March 24, 2015, San Diego, CA.
9. Organized and Chaired a Continuing Education course "Exploring chemical space in the new toxicity testing paradigm: from data curation to computational simulations" at the 2016 Society of Toxicology Annual Meeting, March 13, 2016, New Orleans, LA.
10. Organized and Chaired an EPA Workshop "Aggregate Exposure Pathway: a conceptual framework to advance exposure science research and complete the source-to-outcome continuum for risk assessment". May 9 -11, 2016, Research Triangle Park, NC.
11. Organized and Chaired a Joint Research Centre Workshop "Physiologically-based kinetic modeling in risk assessment – reaching a whole new level in regulatory decision-making", November 17 – 18, 2016, Ispra, Italy.
12. Organized and Chaired a Workshop "Improving public health through innovations in exposure science" at the 2017 Society of Toxicology Annual Meeting, March 13, 2017, Baltimore, MD.
13. Organized and Chaired an ILSI Health and Environmental Sciences Institute (HESI) workshop "PBPK scoping meeting", March 16, 2017, Baltimore, MD.
14. Chairing an Organisation for Economic Co-operation (OECD) project, entitled "Guidance for characterization, evaluation and documenting of physiologically based kinetic models for an integrated strategy in regulatory applications", 2017 – 2020.

15. Organized and Chaired a Continuing Education course “Applications and review of physiologically based pharmacokinetic (PBPK) modeling for regulatory risk assessment” at the 2019 Society of Toxicology Annual Meeting, March 10, 2019, Baltimore, MD.
16. Organized and Chaired a Continuing Education course “A multi-stakeholder dialogue on using proprietary modeling platforms to support risk assessment and regulatory decisions” at the 2019 Society of Toxicology Annual Meeting, March 14, 2019, Baltimore, MD.
17. Lectured at the “PBPK workshop on risk assessment” sponsored by the Republic of Korea’s Ministry of Food and Drug Safety, May 23 – 24, 2019, Seoul, South Korea.
18. Organized and Chaired a virtual symposium on “Opportunities and challenges in using the kinetically derived maximum dose concept to refine risk assessment”, September 30, 2020.
19. Organized and Chaired a virtual symposium “Opportunities and challenges in utilization of toxicokinetic data in dose-level selection for repeated-dose toxicity studies” at the 2021 Society of Toxicology Annual Meeting, March 17, 2019.
20. Guest Lectured on “Applications of physiologically based pharmacokinetic modeling in pesticide risk assessment” for “Introduction to PBTK modeling” at the Emory University, March 18, 2021.
21. Guest Lectured on “Interpreting human biomonitoring data using PBPK models” for “Introduction to PBTK modeling” at the Emory University, April 17, 2021.
22. Organized and presented at an Organisation for Economic Co-operation and Development (OECD) virtual webinar on “Gaining acceptance in next generation PBK modelling”, May 10, 2021.
23. Organized a full-day symposium on “Human Health Paradigms: Exposure, Risk Assessment and Policies for Agrochemicals” at the ACS National Meeting & Exposition, August 25, 2021, Atlanta GA.
24. Organized a virtual workshop on “Challenges and Opportunities for Overcoming Dog Use in Agrochemical Evaluation and Registration”, October 25, 2021.
25. Organized and Chaired a symposium “Leveraging physiologically based pharmacokinetic (PBPK) modeling for refining safety assessment of food, drugs, and chemicals under data-rich and data-poor conditions” at the 2022 Society of Toxicology Annual Meeting, March 28, 2022.
26. Organized and presented at an Organisation for Economic Co-operation and Development (OECD) virtual webinar on “Gaining acceptance in next generation PBK modelling approaches for regulatory approaches: case studies”, April 6, 2022.
27. Organized and chaired and lectured a continuing education course on “A training on the OECD guidance for characterizing, validating, and reporting physiologically based kinetic models”, March 19, 2023.

28. Organized and chaired a roundtable on “Evaluating and rethinking the use of dogs in agrochemical evaluation and registration”, March 20, 2023.

PROFESSIONAL SOCIETY ELECTED APPOINTMENTS

Senior Councilor, Biologically Modeling Specialty Section, Society of Toxicology	2014
President, Biologically Modeling Specialty Section, Society of Toxicology	2013
Vice-President, Biologically Modeling Specialty Section, Society of Toxicology	2012
Vice-President Elect, Biologically Modeling Specialty Section, Society of Toxicology	2011
Councilor, Mixtures Specialty Section, Society of Toxicology	2007 – 2008
Councilor, Biologically Modeling Specialty Section, Society of Toxicology	2006 – 2008
Vice-President Elect, Risk Assessment Specialty Section, Society of Toxicology	2021
Vice-President, Risk Assessment Specialty Section, Society of Toxicology	2022
President, Risk Assessment Specialty Section, Society of Toxicology	2023

ADVISORY APPOINTMENTS

1. Served as a grant proposal reviewer for applications of “Environmental Health and Toxicology Educational Research Program (FOA TS09-003)”. The Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), 2009.
2. Served as an expert reviewer of the “Physiologically Based Pharmacokinetic Model tool-kit” developed for the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), 2010.
3. Served as an expert reviewer of a research application for the Health Canada’s Chemical Management Plan, Monitoring and Surveillance Fund, “Improving interpretation of biomonitoring data for volatile chemical mixtures using physiologically-based pharmacokinetic modelling in humans”, 2011.
4. Served as a member on the Pesticide Program Dialogue Committee 21st Century Toxicology/New Integrated Testing Strategies Workgroup, 2012 – 2016.

5. Served as an expert reviewer of a research application for the Health Canada's Chemical Management Plan, Monitoring and Surveillance Fund, "Reverse Dosimetry to Estimate Human Exposures to Polycyclic Aromatic Hydrocarbons (PAH) in the United States and Canada", 2013.
6. Served as an expert reviewer of a research application for the Health Canada, Exposure and Biomonitoring Division, Healthy Environments and Consumer Safety Branch's Integrated Business Planning & Budgeting Project "Development of reverse dosimetry for pooled biological banked samples for high throughput risk assessment", 2013.
7. Served as a grant proposal reviewer for applications of "Innovative systems toxicology for alternatives to animal testing", The Netherlands Organization for Health Research and Development (ZonMw) and the German Federal Ministry of Education and Research (BMBF), 2015.
8. Served as a grant proposal reviewer for applications of "Collaborative Research on Big Data in Health Research", Pennsylvania Department of Health, 2015.
9. Served as a member on the EPA Risk Assessment Forum, Exposure Oversight Committee, 2012 – 2017.
10. Served as a member on the EPA Risk Assessment Forum, Uncertainty and Variability Technical Panel, 2012 – 2017.
11. Served as a member on a Food & Drug Administration's Science Advisory Subcommittee to review the research conducted in the National Center for Toxicological Research, Division of Biochemical Toxicology, May 12-14, 2021.

BIBLIOGRAPHY

1. Tan YM, DiBerardinis L, Smith T. Exposure assessment of laboratory students. *Appl Occup Environ Hyg.* 1999 Aug;14(8):530-8. doi: 10.1080/104732299302521. PMID: 10462848.
2. Tan YM. and Flynn, M. (2000) Experimental evaluation of a mathematical model for predicting transfer efficiency of a high volume – low pressure air spray gun. *Appl. Occup. Environ. Hyg.* 15(10), 785-793. Tan YM, Flynn MR. Experimental evaluation of a mathematical model for predicting transfer efficiency of a high volume-low pressure air spray gun. *Appl Occup Environ Hyg.* 2000 Oct;15(10):785-93. doi: 10.1080/10473220050129428. PMID: 11036729.
3. Tan YM, Flynn MR. Methods for estimating the transfer efficiency of a compressed air spray gun. *Appl Occup Environ Hyg.* 2002 Jan;17(1):39-46. doi: 10.1080/104732202753306140. PMID: 11800405.

4. Tan YM, Flynn MR, Buller TS. A field evaluation of the impact of transfer efficiency on worker exposure during spray painting. *Ann Occup Hyg.* 2002 Jan;46(1):103-12. doi: 10.1093/annhyg/mef006. PMID: 12005123.
5. Tan YM, Butterworth BE, Gargas ML, Conolly RB. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. *Toxicol Sci.* 2003 Sep;75(1):192-200. doi: 10.1093/toxsci/kfg152. Epub 2003 Jun 12. PMID: 12805651.
6. Andersen ME, Clewell HJ 3rd, Tan YM, Butenhoff JL, Olsen GW. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives. *Toxicology.* 2006 Oct 3;227(1-2):156-64. doi: 10.1016/j.tox.2006.08.004. Epub 2006 Aug 12. PMID: 16978759.
7. Tan YM, Liao KH, Conolly RB, Blount BC, Mason AM, Clewell HJ. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. *J Toxicol Environ Health A.* 2006 Sep;69(18):1727-56. doi: 10.1080/15287390600631367. PMID: 16864423.
8. Barton HA, Chiu WA, Setzer RW, Andersen ME, Bailer AJ, Bois FY, Dewoskin RS, Hays S, Johanson G, Jones N, Loizou G, Macphail RC, Portier CJ, Spendiff M, Tan YM. Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. *Toxicol Sci.* 2007 Oct;99(2):395-402. doi: 10.1093/toxsci/kfm100. Epub 2007 May 4. PMID: 17483121.
9. Liao KH, Tan YM, Conolly RB, Borghoff SJ, Gargas ML, Andersen ME, Clewell HJ 3rd. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. *Risk Anal.* 2007 Dec;27(6):1535-51. doi: 10.1111/j.1539-6924.2007.00987.x. PMID: 18093051.
10. Liao KH, Tan YM, Clewell HJ 3rd. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. *Risk Anal.* 2007 Oct;27(5):1223-36. doi: 10.1111/j.1539-6924.2007.00964.x. PMID: 18076492.
11. Tan YM, Liao KH, Clewell HJ 3rd. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. *J Expo Sci Environ Epidemiol.* 2007 Nov;17(7):591-603. doi: 10.1038/sj.jes.7500540. Epub 2006 Nov 15. PMID: 17108893.
12. LaKind JS, Aylward LL, Brunk C, DiZio S, Dourson M, Goldstein DA, Kilpatrick ME, Krewski D, Bartels MJ, Barton HA, Boogaard PJ, Lipscomb J, Krishnan K, Nordberg M, Okino M, Tan YM, Viau C, Yager JW, Hays SM; Biomonitoring Equivalents Expert Workshop. Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. *Regul Toxicol Pharmacol.* 2008 Aug;51(3 Suppl):S16-26. doi: 10.1016/j.yrtph.2008.05.007. Epub 2008 May 22. PMID: 18579271.

13. Hays SM, Aylward LL, LaKind JS, Bartels MJ, Barton HA, Boogaard PJ, Brunk C, DiZio S, Dourson M, Goldstein DA, Lipscomb J, Kilpatrick ME, Krewski D, Krishnan K, Nordberg M, Okino M, Tan YM, Viau C, Yager JW; Biomonitoring Equivalents Expert Workshop. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. *Regul Toxicol Pharmacol*. 2008 Aug;51(3 Suppl):S4-15. doi: 10.1016/j.yrtph.2008.05.004. Epub 2008 May 22. PMID: 18583008.
14. Chang SC, Das K, Ehresman DJ, Ellefson ME, Gorman GS, Hart JA, Noker PE, Tan YM, Lieder PH, Lau C, Olsen GW, Butenhoff JL. Comparative pharmacokinetics of perfluorobutyrate in rats, mice, monkeys, and humans and relevance to human exposure via drinking water. *Toxicol Sci*. 2008 Jul;104(1):40-53. doi: 10.1093/toxsci/kfn057. Epub 2008 Mar 18. PMID: 18353799.
15. Das KP, Grey BE, Zehr RD, Wood CR, Butenhoff JL, Chang SC, Ehresman DJ, Tan YM, Lau C. Effects of perfluorobutyrate exposure during pregnancy in the mouse. *Toxicol Sci*. 2008 Sep;105(1):173-81. doi: 10.1093/toxsci/kfn099. Epub 2008 May 28. PMID: 18511431.
16. Schroeter JD, Kimbell JS, Gross EA, Willson GA, Dorman DC, Tan YM, Clewell HJ 3rd. Application of physiological computational fluid dynamics models to predict interspecies nasal dosimetry of inhaled acrolein. *Inhal Toxicol*. 2008 Feb;20(3):227-43. doi: 10.1080/08958370701864235. PMID: 18300045.
17. Dorman DC, Struve MF, Wong BA, Gross EA, Parkinson C, Willson GA, Tan YM, Campbell JL, Teeguarden JG, Clewell HJ 3rd, Andersen ME. Derivation of an inhalation reference concentration based upon olfactory neuronal loss in male rats following subchronic acetaldehyde inhalation. *Inhal Toxicol*. 2008 Feb;20(3):245-56. doi: 10.1080/08958370701864250. Erratum in: *Inhal Toxicol*. 2008 Sep;20(12):1119-23. PMID: 18300046.
18. Teeguarden JG, Bogdanffy MS, Covington TR, Tan YM, Jarabek AM. A PBPK model for evaluating the impact of aldehyde dehydrogenase polymorphisms on comparative rat and human nasal tissue acetaldehyde dosimetry. *Inhal Toxicol*. 2008 Feb;20(4):375-90. doi: 10.1080/08958370801903750. PMID: 18302046.
19. Nong A, Tan YM, Krolski ME, Wang J, Lunchick C, Conolly RB, Clewell HJ 3rd. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. *J Toxicol Environ Health A*. 2008;71(20):1363-81. doi: 10.1080/15287390802271608. PMID: 18704829.
20. Clewell HJ, Tan YM, Campbell JL, Andersen ME. Quantitative interpretation of human biomonitoring data. *Toxicol Appl Pharmacol*. 2008 Aug 15;231(1):122-33. doi: 10.1016/j.taap.2008.04.021. Epub 2008 May 4. PMID: 18589468.

21. Tan YM, Clewell HJ 3rd, Andersen ME. Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. *Toxicol Lett.* 2008 Feb 28;177(1):38-47. doi: 10.1016/j.toxlet.2007.12.007. Epub 2007 Dec 27. PMID: 18242015.
22. Clewell H, Tan YM, and Andersen M. Simulation modeling of PFAA exposure and pharmacokinetics. *Repro Tox.* 2009;27(3), 410. doi: 10.1016/j.reprotox.2008.11.006.
23. Sweeney LM, Kirman CR, Albertini RJ, Tan YM, Clewell HJ, Filser JG, Csanády G, Pottenger LH, Banton MI, Graham CJ, Andrews LS, Papciak RJ, Gargas ML. Derivation of inhalation toxicity reference values for propylene oxide using mode of action analysis: example of a threshold carcinogen. *Crit Rev Toxicol.* 2009;39(6):462-86. doi: 10.1080/10408440902837959. PMID: 19545197.
24. Yang Y, Allen BC, Tan YM, Liao KH, Clewell HJ 3rd. Bayesian analysis of a rat formaldehyde DNA-protein cross-link model. *J Toxicol Environ Health A.* 2010;73(12):787-806. doi: 10.1080/15287391003689234. PMID: 20391121.
25. Tardiff RG, Carson ML, Sweeney LM, Kirman CR, Tan YM, Andersen M, Bevan C, Gargas ML. Derivation of a drinking water equivalent level (DWEL) related to the maximum contaminant level goal for perfluorooctanoic acid (PFOA), a persistent water soluble compound. *Food Chem Toxicol.* 2009 Oct;47(10):2557-89. doi: 10.1016/j.fct.2009.07.016. Epub 2009 Jul 22. PMID: 19631249.
26. Sobus JR, Tan YM, Pleil JD, Sheldon LS. A biomonitoring framework to support exposure and risk assessments. *Sci Total Environ.* 2011 Oct 15;409(22):4875-84. doi: 10.1016/j.scitotenv.2011.07.046. Epub 2011 Sep 8. PMID: 21906784.
27. Tan YM, Clewell H, Campbell J, Andersen M. Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment. *Int J Environ Res Public Health.* 2011 May;8(5):1613-30. doi: 10.3390/ijerph8051613. Epub 2011 May 19. PMID: 21655141; PMCID: PMC3108131.
28. Tan YM, Sobus J, Chang D, Tornero-Velez R, Goldsmith M, Pleil J, Dary C. Reconstructing human exposures using biomarkers and other "clues". *J Toxicol Environ Health B Crit Rev.* 2012;15(1):22-38. doi: 10.1080/10937404.2012.632360. PMID: 22202228.
29. Yang Y, Tan YM, Blount B, Murray C, Egan S, Bolger M, Clewell H. Using a physiologically based pharmacokinetic model to link urinary biomarker concentrations to dietary exposure of perchlorate. *Chemosphere.* 2012 Aug;88(8):1019-27. doi: 10.1016/j.chemosphere.2012.03.074. Epub 2012 Apr 20. PMID: 22520969.
30. Grulke CM, Holm K, Goldsmith MR, Tan YM. PROCEED: Probabilistic reverse dosimetry approaches for estimating exposure distributions. *Bioinformatics.* 2013 Jul 17;9(13):707-9. doi: 10.6026/97320630009707. PMID: 23930024; PMCID: PMC3732445.

31. Goldsmith MR, Grulke CM, Brooks RD, Transue TR, Tan YM, Frame A, Egeghy PP, Edwards R, Chang DT, Tornero-Velez R, Isaacs K, Wang A, Johnson J, Holm K, Reich M, Mitchell J, Vallero DA, Phillips L, Phillips M, Wambaugh JF, Judson RS, Buckley TJ, Dary CC. Development of a consumer product ingredient database for chemical exposure screening and prioritization. *Food Chem Toxicol.* 2014 Mar;65:269-79. doi: 10.1016/j.fct.2013.12.029. Epub 2013 Dec 27. PMID: 24374094.
32. Breen MS, Long TC, Schultz BD, Crooks J, Breen M, Langstaff JE, Isaacs KK, Tan YM, Williams RW, Cao Y, Geller AM, Devlin RB, Batterman SA, Buckley TJ. GPS-based microenvironment tracker (MicroTrac) model to estimate time-location of individuals for air pollution exposure assessments: model evaluation in central North Carolina. *J Expo Sci Environ Epidemiol.* 2014 Jul;24(4):412-20. doi: 10.1038/jes.2014.13. Epub 2014 Mar 12. PMID: 24619294; PMCID: PMC4269558.
33. Phillips MB, Sobus JR, George BJ, Isaacs K, Conolly R, Tan YM. A new method for generating distributions of biomonitoring equivalents to support exposure assessment and prioritization. *Regul Toxicol Pharmacol.* 2014 Aug;69(3):434-42. doi: 10.1016/j.yrtph.2014.05.008. Epub 2014 May 17. PMID: 24845241.
34. Lehmann GM, Verner MA, Luukinen B, Henning C, Assimon SA, LaKind JS, McLanahan ED, Phillips LJ, Davis MH, Powers CM, Hines EP, Haddad S, Longnecker MP, Poulsen MT, Farrer DG, Marchitti SA, Tan YM, Swartout JC, Sagiv SK, Welsh C, Campbell JL Jr, Foster WG, Yang RS, Fenton SE, Tornero-Velez R, Francis BM, Barnett JB, El-Masri HA, Simmons JE. Improving the risk assessment of lipophilic persistent environmental chemicals in breast milk. *Crit Rev Toxicol.* 2014 Aug;44(7):600-17. doi: 10.3109/10408444.2014.926306. PMID: 25068490; PMCID: PMC4115797.
35. LaKind JS, Sobus JR, Goodman M, Barr DB, Fürst P, Albertini RJ, Arbuckle TE, Schoeters G, Tan YM, Teeguarden J, Tornero-Velez R, Weisel CP. A proposal for assessing study quality: Biomonitoring, Environmental Epidemiology, and Short-lived Chemicals (BEES-C) instrument. *Environ Int.* 2014 Dec;73:195-207. doi: 10.1016/j.envint.2014.07.011. Epub 2014 Aug 17. PMID: 25137624; PMCID: PMC4310547.
36. Christensen K, Sobus J, Phillips M, Blessinger T, Lorber M, Tan YM. Changes in epidemiologic associations with different exposure metrics: a case study of phthalate exposure associations with body mass index and waist circumference. *Environ Int.* 2014 Dec;73:66-76. doi: 10.1016/j.envint.2014.07.010. Epub 2014 Aug 2. PMID: 25090576.
37. Phillips MB, Yoon M, Young B, Tan YM. Analysis of biomarker utility using a PBPK/PD model for carbaryl. *Front Pharmacol.* 2014 Nov 18;5:246. doi: 10.3389/fphar.2014.00246. PMID: 25477820; PMCID: PMC4235294.

38. Yin Y, Chang D, Grulke C, Tan YM, Goldsmith MR, Tornero-Velez R. Essential set of molecular descriptors for ADME prediction in drug and environmental chemical space. *Research*. 2014;1,996, doi:10.13070/rs.en.1.996.
39. Sobus JR, DeWoskin RS, Tan YM, Pleil JD, Phillips MB, George BJ, Christensen K, Schreinemachers DM, Williams MA, Hubal EA, Edwards SW. Uses of NHANES Biomarker Data for Chemical Risk Assessment: Trends, Challenges, and Opportunities. *Environ Health Perspect*. 2015 Oct;123(10):919-27. doi: 10.1289/ehp.1409177. Epub 2015 Apr 10. PMID: 25859901; PMCID: PMC4590763.
40. Brown K, Phillips M, Grulke C, Yoon M, Young B, McDougall R, Leonard J, Lu J, Lefew W, Tan YM. Reconstructing exposures from biomarkers using exposure-pharmacokinetic modeling--A case study with carbaryl. *Regul Toxicol Pharmacol*. 2015 Dec;73(3):689-98. doi: 10.1016/j.yrtph.2015.10.031. Epub 2015 Nov 7. PMID: 26545325.
41. Phillips MB, Leonard JA, Grulke CM, Chang DT, Edwards SW, Brooks R, Goldsmith MR, El-Masri H, Tan YM. A Workflow to Investigate Exposure and Pharmacokinetic Influences on High-Throughput in Vitro Chemical Screening Based on Adverse Outcome Pathways. *Environ Health Perspect*. 2016 Jan;124(1):53-60. doi: 10.1289/ehp.1409450. Epub 2015 May 15. PMID: 25978103; PMCID: PMC4710605.
42. Lu J, Goldsmith MR, Grulke CM, Chang DT, Brooks RD, Leonard JA, Phillips MB, Hypes ED, Fair MJ, Tornero-Velez R, Johnson J, Dary CC, Tan YM. Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction. *PLoS Comput Biol*. 2016 Feb 12;12(2):e1004495. doi: 10.1371/journal.pcbi.1004495. PMID: 26871706; PMCID: PMC4752336.
43. Edwards SW, Tan YM, Villeneuve DL, Meek ME, McQueen CA. Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making. *J Pharmacol Exp Ther*. 2016 Jan;356(1):170-81. doi: 10.1124/jpet.115.228239. Epub 2015 Nov 4. PMID: 26537250.
44. Leonard JA, Tan YM, Gilbert M, Isaacs K, El-Masri H. Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-Throughput in vitro Data, High-Throughput Exposure Modeling, and Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling. *Toxicol Sci*. 2016 May;151(1):57-70. doi: 10.1093/toxsci/kfw022. Epub 2016 Feb 10. PMID: 26865668; PMCID: PMC4914794.
45. Teeguarden JG, Tan YM, Edwards SW, Leonard JA, Anderson KA, Corley RA, Kile ML, Simonich SM, Stone D, Tanguay RL, Waters KM, Harper SL, Williams DE. Completing the Link between Exposure Science and Toxicology for Improved Environmental Health Decision Making: The Aggregate Exposure Pathway Framework. *Environ Sci Technol*. 2016 May 3;50(9):4579-86. doi: 10.1021/acs.est.5b05311. Epub 2016 Feb 10. PMID: 26759916; PMCID: PMC4854780.

46. Teeguarden JG, Tan YM, Edwards SW, Leonard JA, Anderson KA, Corley RA, Kile ML, L Massey Simonich S, Stone D, Tanguay RL, Waters KM, Harper SL, Williams DE. Expanding on Successful Concepts, Models, and Organization. *Environ Sci Technol*. 2016 Sep 6;50(17):8921-2. doi: 10.1021/acs.est.6b03027. Epub 2016 Aug 10. PMID: 27509267.
47. El-Masri H, Kleinstreuer N, Hines RN, Adams L, Tal T, Isaacs K, Wetmore BA, Tan YM. Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards. *Toxicol Sci*. 2016 Jul;152(1):230-43. doi: 10.1093/toxsci/kfw082. Epub 2016 May 4. PMID: 27208077; PMCID: PMC5009469.
48. Leonard JA, Sobel Leonard A, Chang DT, Edwards S, Lu J, Scholle S, Key P, Winter M, Isaacs K, Tan YM. Evaluating the Impact of Uncertainties in Clearance and Exposure When Prioritizing Chemicals Screened in High-Throughput Assays. *Environ Sci Technol*. 2016 Jun 7;50(11):5961-71. doi: 10.1021/acs.est.6b00374. Epub 2016 May 12. PMID: 27124219; PMCID: PMC5783724.
49. Csiszar SA, Meyer DE, Dionisio KL, Egeghy P, Isaacs KK, Price PS, Scanlon KA, Tan YM, Thomas K, Vallero D, Bare JC. Conceptual Framework To Extend Life Cycle Assessment Using Near-Field Human Exposure Modeling and High-Throughput Tools for Chemicals. *Environ Sci Technol*. 2016 Nov 1;50(21):11922-11934. doi: 10.1021/acs.est.6b02277. Epub 2016 Oct 18. PMID: 27668689; PMCID: PMC7388028.
50. Escher BI, Hackermüller J, Polte T, Scholz S, Aigner A, Altenburger R, Böhme A, Bopp SK, Brack W, Busch W, Chadeau-Hyam M, Covaci A, Eisenträger A, Galligan JJ, Garcia-Reyero N, Hartung T, Hein M, Herberth G, Jahnke A, Kleinjans J, Klüver N, Krauss M, Lamoree M, Lehmann I, Luckenbach T, Miller GW, Müller A, Phillips DH, Reemtsma T, Rolle-Kampczyk U, Schüürmann G, Schwikowski B, Tan YM, Trump S, Walter-Rohde S, Wambaugh JF. From the exposome to mechanistic understanding of chemical-induced adverse effects. *Environ Int*. 2017 Feb;99:97-106. doi: 10.1016/j.envint.2016.11.029. Epub 2016 Dec 8. PMID: 27939949; PMCID: PMC6116522.
51. Moreau M, Leonard J, Phillips KA, Campbell J, Pendse SN, Nicolas C, Phillips M, Yoon M, Tan YM, Smith S, Pudukodu H, Isaacs K, Clewell H. Using exposure prediction tools to link exposure and dosimetry for risk-based decisions: A case study with phthalates. *Chemosphere*. 2017 Oct;184:1194-1201. doi: 10.1016/j.chemosphere.2017.06.098. Epub 2017 Jun 24. PMID: 28672700; PMCID: PMC6084441.
52. Lee S, Tan YM, Phillips MB, Sobus JR, Kim S. Estimating Methylmercury Intake for the General Population of South Korea Using Physiologically Based Pharmacokinetic Modeling. *Toxicol Sci*. 2017 Sep 1;159(1):6-15. doi: 10.1093/toxsci/kfx111. PMID: 28903490; PMCID: PMC6145084.
53. Leonard JA, Stevens C, Mansouri K, Chang D, Pudukodu H, Smith S, Tan YM. A Workflow for Identifying Metabolically Active Chemicals to Complement in vitro Toxicity Screening. *Comput*

Toxicol. 2018 May;6:71-83. doi: 10.1016/j.comtox.2017.10.003. PMID: 30246166; PMCID: PMC6145457.

54. Paini A, Leonard JA, Kliment T, Tan YM, Worth A. Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications. *Regul Toxicol Pharmacol.* 2017 Nov;90:104-115. doi: 10.1016/j.yrtph.2017.08.019. Epub 2017 Sep 1. PMID: 28866268; PMCID: PMC5656087.
55. Tan YM, Worley RR, Leonard JA, Fisher JW. Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making. *Toxicol Sci.* 2018 Apr 1;162(2):341-348. doi: 10.1093/toxsci/kfy010. Erratum in: *Toxicol Sci.* 2018 Apr 1;162(2):724. PMID: 29385573; PMCID: PMC6084449.
56. Tan YM, Leonard JA, Edwards S, Teeguarden J, Egeghy P. Refining the aggregate exposure pathway. *Environ Sci Process Impacts.* 2018 Mar 1;20(3):428-436. doi: 10.1039/c8em00018b. Epub 2018 Feb 21. PMID: 29465734; PMCID: PMC5909835.
57. Chen SH, Sung YF, Oyarzabal EA, Tan YM, Leonard J, Guo M, Li S, Wang Q, Chu CH, Chen SL, Lu RB, Hong JS. Physiological Concentration of Prostaglandin E2 Exerts Anti-inflammatory Effects by Inhibiting Microglial Production of Superoxide Through a Novel Pathway. *Mol Neurobiol.* 2018 Oct;55(10):8001-8013. doi: 10.1007/s12035-018-0965-4. Epub 2018 Mar 1. PMID: 29492849; PMCID: PMC6119547.
58. Tan YM, Leonard JA, Edwards S, Teeguarden J, Paini A, Egeghy P. Aggregate Exposure Pathways in Support of Risk Assessment. *Curr Opin Toxicol.* 2018 Jun;9:8-13. doi: 10.1016/j.cotox.2018.03.006. Epub 2018 Mar 29. PMID: 29736486; PMCID: PMC5935252.
59. Madden JC, Pawar G, Cronin M, Webb S, Tan YM, Paini A. In silico resources to assist in the development and evaluation of physiologically-based kinetic models. *Comp Toxicol* 2019;11, 33-49. doi:10.1016/j.comtox.2019.03.001.
60. Paini A, Leonard JA, Joossens E, Bessems JGM, Desalegn A, Dorne JL, Gosling JP, Heringa MB, Klaric M, Kliment T, Kramer NI, Loizou G, Louisse J, Lumen A, Madden JC, Patterson EA, Proença S, Punt A, Setzer RW, Suci N, Troutman J, Yoon M, Worth A, Tan YM. Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making. *Comput Toxicol.* 2019 Feb;9:61-72. doi: 10.1016/j.comtox.2018.11.002. PMID: 31008414; PMCID: PMC6472623.
61. Leonard JA, Nelms M, Craig E, Perron M, Pope-Varsalona H, Dobreniecki S, Lowit A, Tan YM. A weight of evidence approach to investigate potential common mechanisms in pesticide groups to support cumulative risk assessment: A case study with dinitroaniline pesticides. *Regul Toxicol Pharmacol.* 2019 Oct;107:104419. doi: 10.1016/j.yrtph.2019.104419. Epub 2019 Jul 10. PMID: 31301330.

62. Leonard J and Tan YM. Tiered approaches for screening and prioritizing chemicals through integration of pharmacokinetics and exposure information with in vitro dose-response data. *Comput Toxicol.* 2019;12, 100101. doi: 10.1016/j.comtox.2019.100101.
63. Clewell RA, Leonard JA, Nicolas CI, Campbell JL, Yoon M, Efremenko AY, McMullen PD, Andersen ME, Clewell HJ 3rd, Phillips KA, Tan YM. Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates. *Toxicol In Vitro.* 2020 Aug;66:104855. doi: 10.1016/j.tiv.2020.104855. Epub 2020 Apr 8. PMID: 32278033; PMCID: PMC8204916.
64. Tan YM, Chan M, Chukwudebe A, Domoradzki J, Fisher J, Hack CE, Hinderliter P, Hirasawa K, Leonard J, Lumen A, Paini A, Qian H, Ruiz P, Wambaugh J, Zhang F, Embry M. PBPK model reporting template for chemical risk assessment applications. *Regul Toxicol Pharmacol.* 2020 Aug;115:104691. doi: 10.1016/j.yrtph.2020.104691. Epub 2020 Jun 2. PMID: 32502513; PMCID: PMC8188465.
65. Madden J, Tan YM, Blaauboer B, Paini A. Development and application of physiologically-based kinetic (PBK) models. *Comput Toxicol.* 2020. doi:10.1016/j.comtox.2019.100116.
66. Paini A, Tan YM, Sachana M, Worth A. Gaining acceptance in next generation PBK modelling approaches for regulatory assessments - An OECD international effort. *Comput Toxicol.* 2021 May;18:100163. doi: 10.1016/j.comtox.2021.100163. PMID: 34027244; PMCID: PMC8130668.
67. Tan YM, Barton HA, Boobis A, Brunner R, Clewell H, Cope R, Dawson J, Domoradzki J, Egeghy P, Gulati P, Ingle B, Kleinstreuer N, Lowe K, Lowit A, Mendez E, Miller D, Minucci J, Nguyen J, Paini A, Perron M, Phillips K, Qian H, Ramanarayanan T, Sewell F, Villanueva P, Wambaugh J, Embry M. Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment. *Regul Toxicol Pharmacol.* 2021 Dec;127:105070. doi: 10.1016/j.yrtph.2021.105070. Epub 2021 Oct 28. PMID: 34718074; PMCID: PMC9229944.
68. Lowe K, Dawson J, Phillips K, Minucci J, Wambaugh JF, Qian H, Ramanarayanan T, Egeghy P, Ingle B, Brunner R, Mendez E, Embry M, Tan YM. Incorporating human exposure information in a weight of evidence approach to inform design of repeated dose animal studies. *Regul Toxicol Pharmacol.* 2021 Dec;127:105073. doi: 10.1016/j.yrtph.2021.105073. Epub 2021 Oct 29. PMID: 34743952; PMCID: PMC8767482.
69. Thompson CV, Firman JW, Goldsmith MR, Grulke CM, Tan YM, Paini A, Penson PE, Sayre RR, Webb S, Madden JC. A Systematic Review of Published Physiologically-based Kinetic Models and an Assessment of their Chemical Space Coverage. *Altern Lab Anim.* 2021 Sep;49(5):197-208. doi: 10.1177/02611929211060264. Epub 2021 Nov 26. PMID: 34836462; PMCID: PMC8764633.
70. Chang X, Tan YM, Allen DG, Bell S, Brown PC, Browning L, Ceger P, Gearhart J, Hakkinen PJ, Kabadi SV, Kleinstreuer NC, Lumen A, Matheson J, Paini A, Pangburn HA, Petersen EJ, Reinke EN, Ribeiro AJS, Sipes N, Sweeney LM, Wambaugh JF, Wange R, Wetmore BA, Mumtaz M. IVIVE:

Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making. *Toxics*. 2022 May 1;10(5):232. doi: 10.3390/toxics10050232. PMID: 35622645; PMCID: PMC9143724.

71. Hoer D, Barton HA, Paini A, Bartels M, Ingle B, Domoradzki J, Fisher J, Embry M, Villanueva P, Miller D, Nguyen J, Zhang Q, Edwards SW, Tan YM. Predicting nonlinear relationships between external and internal concentrations with physiologically based pharmacokinetic modeling. *Toxicol Appl Pharmacol*. 2022 Apr 1;440:115922. doi: 10.1016/j.taap.2022.115922. Epub 2022 Feb 15. PMID: 35176293.

BOOK CHAPTERS

1. Qiang, Z., Tan, Y., Bhattacharya, S., Andersen, M. (2008). Computational systems biology modeling of dosimetry and cellular response pathways. In *Drug Efficacy, Safety, and Biologics Discovery – Emerging Technologies and Tools*. Ekins S. and Xu J. (ed), John Wiley & Sons, Hoboken, NJ.
2. Tan, Y. and Clewell, H. (2010). Probabilistic reverse dosimetry modeling for interpreting biomonitoring data. In *Quantitative Modeling in Toxicology*. Krishnan K. and Andersen M. (ed), John Wiley & Sons, Hoboken, NJ.
3. Tan, Y., Yang, Y., Andersen, M., Clewell, H. (2011). Exposure science: Pharmacokinetic modeling. In *Encyclopedia of Environmental Health*. Nriagu J. (ed), Elsevier Science, Amsterdam; London.
4. Knaak, J., Tan, Y., Dary, C. (2012). Pesticide regulations: exposure-dose modeling from FIFRA to FQPA. In *Toxicology and Human Environments*. Hodgson, E. (ed), Elsevier Science, NY.
5. Chang, D., Goldsmith, R., Tornero-Velez, R., Tan, Y., Grulke, C., Chen, L., Ulrich, E., Lindstrom, A., Pasquinelli, M., Rabinowitz, J., Dary, C. (2012). In silico strategies for modeling stereoselective metabolism of pyrethroids. In *Toxicology and Human Environments*. Hodgson, E. (ed), Elsevier Science, NY.
6. Tan, Y., Conolly, R., Chang, D., Tornero-Velez, R., Goldsmith, R., Peterson, S., and Dary, C. (2013). Computational toxicology – application in environmental chemicals. In *Methods in Molecular Biology – Computational Toxicology Vol 929*. Reisfeld, B. and Mayeno, A. (ed), Humana Press, NY.
7. Goldsmith, R., Peterson, S., Chang, D., Transue, T., Tornero-Velez, R., Tan, Y. and Dary, C. (2013). Informing mechanistic toxicology with computational molecular models. In *Methods in Molecular Biology – Computational Toxicology Vol 929*. Reisfeld, B. and Mayeno, A. (ed), Humana Press, NY.

8. Tan, Y., Chang, D., Phillips, M., Edwards, S., Grulke, C., Goldsmith, M., Sobus, J., Conolly, R., Tornero-Velez, R., Dary, C. (2013). Biomarkers in computational toxicology. In *Biomarkers in Toxicology*, Gupta, R. (ed), Elsevier.
9. Tan, Y., Phillips, M., Sobus, J., Chang, D., Goldsmith, M. (2014). Biomarkers – key to exposure reconstruction. In *McGraw-Hill Yearbook of Science and Technology 2014*, McGraw-Hill.
10. Chang, D., Goldsmith, M., Grulke, C., Egeghy, P., Tan, Y., Mitchell-Blackwood, J. (2014). Data mining and informatics-based approach for new and emerging environmental contaminants. In *McGraw-Hill Yearbook of Science and Technology 2014*, McGraw-Hill.
11. Goldsmith, M., Grulke, C., Chang, D., Tan, Y., Brooks, R., Dary, C., Vallerio, D. (2014). Personal chemical exposure informatics. In *McGraw-Hill Yearbook of Science and Technology 2014*, McGraw-Hill.
12. Oki, N., Leonard, J., Nelms, M., Bell, S., Tan, Y., Burgoon, L., Edwards, S. (2017). Linking environmental exposure to toxicity. In *Computational Systems Pharmacology and Toxicology*, Johnson, D. and Richardson, R. (ed), Royal Society of Chemistry.
13. Leonard, J., Bell, S., Oki, N., Nelms, M., Tan, Y., Edwards, S. (2016). Tiered approaches to incorporate the adverse outcome pathway framework into chemical-specific regulatory decision making. In *A Systems Biology Approach to Advancing Adverse Outcome Pathways for Risk Assessment*, Garcia-Reyero, N. and Murphy, C. (ed), Springer Publishing Company. doi: 10.1007/978-3-319-66084-4_12.

TECHNICAL REPORTS AND GUIDANCE DOCUMENT

1. Tan, Y., Dary, C., Chang, D., Ulrich, E., Van Emon, J., Xue, J., Pleil, J., Kenneke, J., Sobus, J., Sheldon, L., Morgan, M., Goldsmith, R., Tornero-Velez, R., Highsmith, R., Fortmann, R., Collette, T., Zartarian, V. (2012). Biomonitoring – an exposure science tool for exposure and risk assessment. EPA technical report.
2. Goldsmith, R., Tan, Y., Chang, D., Grulke, C., Tornero-Velez, R., Vallerio, D., Dary, C., Johnson, J., Egeghy, P., Mitchell-Blackwood, J., Holm, K., Reich, M., Edwards, R., Phillips, L. (2013). Summary report for Personal Chemical Exposure Informatics: Visualization and Exploratory Research in Simulations and Systems (PerCEVIERS). EPA technical report.
3. OECD (2021), Guidance document on the characterisation, validation and reporting of Physiologically Based Kinetic (PBK) models for regulatory purposes, OECD Series on Testing and Assessment, No. 331, Environment, Health and Safety, Environment Directorate, OECD.

INVITED PRESENTATIONS

1. "Tiered approaches for linking ADME to adverse outcome pathways". American Chemistry Council webinar, July 22, 2015.
2. "Biomarkers in risk assessment: use, challenges, and lessons learned". The Food & Drug Administration Workshop "Biomarkers of tobacco exposure", August 3 – 4, 2015, Silver Spring, MD.
3. "Tools in support of PK and ADME profiling". Invited presentation at the LRSS Workshop "Refining the safety assessment approach – linking consumer exposure scenarios to internal exposure", September 21 – 22, 2015, Brussels, Belgium.
4. "Pieces of the puzzle: tracking the chemical component of the exposome". Expert Workshop on Exposome, December 14 – 15, 2015, Leipzig, Germany.
5. "Exposome thinking at EPA". Emory Exposome Summer Course, June 13 – 17, 2016, Atlanta, GA.
6. "Physiologically based pharmacokinetic (PBPK) modeling". EPA Office of Pesticides Program Toxicology Training, April 5, 2016, Arlington, VA.
7. "Physiologically based pharmacokinetic (PBPK) modeling for pregnancy and early lifestages". EPA Office of Children's Health Protection, August 10, 2016, Washington D.C.
8. "Applications of physiologically-based pharmacokinetic modeling in risk assessment in the U.S." Joint Research Centre Expert Workshop on Physiologically-based kinetic modeling in risk assessment – reaching a whole new level in regulatory decision-making, November 17 – 18, 2016, Ispra, Italy.
9. "Aggregate Exposure Pathway (AEP): a conceptual framework for advancing exposure science research and applications". Joint ISES-SOT webinar, December 14, 2016.
10. "Complementing *in vitro* screening assays with *in silico* molecular chemistry tools to examine potential *in vivo* metabolite-mediated effects". Society of Toxicology Annual Meeting, March 13, 2017, Baltimore, MD.
11. "Aggregate Exposure Pathways (AEPs) as a means to advance exposure science research & connect exposure with AOPs". Joint Research Centre webinar, May 22, 2017.
12. "Integrating Aggregate Exposure Pathway (AEP) and Adverse Outcome Pathway (AOP) frameworks to estimate exposure-relevant responses". 2017 ICCA-LRI & JRC workshop on Fit-for-purpose exposure assessments for risk-based decision-making. Como, Italy, June 22, 2017.
13. "Applying Aggregate Exposure Pathway and Adverse Outcome Pathway frameworks to link toxicity testing data to exposure-relevant and biologically-relevant responses". OpenTox USA 2017, July 13, 2017, Durham, NC.

14. "Frameworks for organizing exposure and toxicity data – the Aggregate Exposure Pathway (AEP) and the Adverse Outcome Pathway (AOP)". 2017 ISES Annual Meeting, October 18, 2017, Durham, NC.
15. "Physiologically-based kinetic modelling in risk assessment – reaching a whole new level in regulatory decision-making". 2017 ISES Annual Meeting, October 17, 2017, Durham, NC.
16. "A tiered approach to incorporate exposure and pharmacokinetics consideration in *in vitro*-based safety assessment". 2018 Society of Toxicology Annual Meeting, Continuing Education course on "Physiologically-based pharmacokinetic modeling to support modernized chemical safety assessment", March 11, 2018, San Antonio, TX.
17. "General concept of human health assessment". PBPK workshop on risk assessment, May 23-24, 2019, Seoul, South Korea.
18. "Interpreting human biomonitoring data using PBPK models". PBPK workshop on risk assessment, May 23-24, 2019, Seoul, South Korea.
19. "PBPK applications in risk assessment". PBPK workshop on risk assessment, May 23-24, 2019, Seoul, South Korea.
20. "Applications of physiologically based pharmacokinetic modeling in pesticide risk assessment", Scitovation webinar, March 30, 2021.
21. "Physiologically based pharmacokinetic (PBPK) model reporting template for chemical risk assessment applications", Society of Toxicology, Biological Modeling Specialty Section webinar, November 11, 2021.
22. "Applying physiologically based pharmacokinetic (PBPK) modeling to design and optimize animal toxicity studies". International Congress of Toxicology 2022 Annual Meeting symposium session "Putting the puzzle together: multiple lines of evidence to inform design and interpretation of long-term, repeated-dose animal studies for human health risk assessment", September 21, 2022.
23. "Overcoming challenges in accepting PBPK models for regulatory applications". NURA Human In, Human Out: Using primary and population data for PBPK analyses, hosted by Physicians Committee for Responsible Medicine, November 17, 2022.
24. "PBPK regulatory applications". The 3rd Annual virtual Model Informed Drug Development + (MIDD+) Conference by Simulations Plus, February 16, 2023.

PRESENTATIONS

1. Tan, Y., Butterworth, B., Conolly, R. (2003). A threshold linkage between chloroform induced cellular damage and cytolethality provides a better fit to hepatic labeling index data than a linear linkage. Abstract 673. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 72, Number S-1.
2. Tan, Y. and Conolly, R. (2004). The contribution of pharmacokinetic variability to variability in hepatic labeling index data from B6C3F1 mice exposed to chloroform. Abstract 1759. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 78, Number S-1.
3. Wang, J., Tan, Y., Tobia, A., Lunchick, C., Krolski, M., Conolly, R. (2005). Physiologically based pharmacokinetic/pharmacodynamic modeling for the n-methyl carbamate pesticide carbaryl: insight into mechanism and risk assessment. Abstract 1297. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 84, Number S-1.
4. Tan, Y. and Conolly, R. (2005). Monte Carlo analysis of sources of variability in chloroform-induced hepatic cytolethality and regenerative proliferation in B6C3F1 mice. Abstract 404. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 84, Number S-1.
5. Liao, K., Conolly, R., Mason, A., Tan, Y. (2005). Use of a physiologically based pharmacokinetic model for chloroform to evaluate biomonitoring data. Abstract 403. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 84, Number S-1.
6. Conolly, R., Wang, J., and Tan, Y. (2005). Physiologically based pharmacokinetic (PBPK) modeling as an alternative to relative potency factors (RPFs) in cumulative risk assessment: an example with acetylcholinesterase (AChE) inhibiting pesticides. Abstract 34. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 84, Number S-1.
7. Liao, K., Tan, Y., Conolly, R., Andersen, M., Clewell, H. (2006). Use of Markov Chain Monte Carlo analysis to estimate the pharmacokinetic and pharmacodynamic parameters required for a mode-of-action based cancer risk assessment for chloroform. Abstract 2310. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 90, Number S-1.
8. Conolly, R., Liao, K., Tan, Y. (2006) Use of physiologically based pharmacokinetic modeling to characterize exposures associated with biomonitoring data. Abstract 1875. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 90, Number S-1.
9. Mason, A., Clewell, H., Liao, K., Tan, Y. (2006). Reconstructing human trihalomethanes exposure from biomonitoring data with physiologically based pharmacokinetic models. Abstract 1271. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 90, Number S-1.
10. Clewell, H., Tan, Y., Liao, K. (2006). Development of a reverse dosimetry screening approach for the interpretation of biomonitoring data on volatile organic compounds. Abstract 1886. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 90, Number S-1.

11. Tan, Y., Kimbell, J., Conolly, R., Clewell, H. (2006) Evaluation of the tumor dose response for propylene oxide using CFD modeling and the 2-stage clonal growth model. Abstract 1885. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 90, Number S-1.
12. Clewell, H., Nong, A., Tan, Y. (2007). Bayesian physiologically based pharmacokinetic /pharmacodynamic (PBPK/PD) modeling of mixed route exposure of carbaryl. Abstract 1690. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 96, Number S-1.
13. Yang, Y., Liao, K., Allen, B., Tan, Y., Clewell, H. (2007) Characterization of sensitivity of risk estimates to uncertainties associated with biologically based modeling of formaldehyde carcinogenicity. Abstract 1606. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 96, Number S-1.
14. Chang, S., Hart, J., Ehresman, D., Das, K., Lau, C., Noker, P., Gorman, G., Tan, Y., Butenhoff, J. (2007). Comparative pharmacokinetics of perfluorobutyrate (PFBA) in rats, mice, and monkeys. Abstract 937. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 96, Number S-1.
15. Tan, Y., Clewell, H., Butenhoff, J., Olsen, G., Andersen, M. (2007). Physiologically-motivated pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacides in monkeys and rats. Abstract 386. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 96, Number S-1.
16. Yang, Y., Allen, B., Tan, Y., Clewell, H. (2008). Sequential Bayesian analysis of the formaldehyde cancer model, Part 2, calibration of rat clonal growth model. Abstract 1007. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 102, Number S-1.
17. Tan, Y., Clewell, H., Andersen, M. (2008). Understanding the complexity in kinetics of perfluorooctylacids in monkeys and rats using a pharmacokinetic model. Abstract 1010. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 102, Number S-1.
18. Campbell, J., Clewell, R., Tan, Y., Clewell, H. (2008). Interpreting biomonitoring data for monobutyl phthalate in urine using a physiologically based pharmacokinetic model: estimation of in utero exposure. *Epidemiology*, 19(6), S248.
19. Kedderis, G., Yoon, M., Tan, Y., Clewell, H. (2009). Kinetics of carbaryl biotransformation by freshly isolated Sprague-Dawley rat hepatocytes. Abstract 1158. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 108, Number S-1.
20. Yang, Y., Clewell, H., Tan, Y., Andersen, M., Sochaski, M., Himmelstein, M. (2009). In vitro to in vivo extrapolation with a PBTK model for 2-chloro-1,3-butadiene. Abstract 962. *The Toxicologist — An Official Journal of the Society of Toxicology*, Volume 108, Number S-1.

21. Campbell, J., Tan, Y., Clewell, H. (2009). Development of a PBPK model for hexavalent chromium in rats and mice to estimate exposure to oral mucosa and small intestine epithelium. Abstract 469. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 108, Number S-1.
22. Tan, Y., Yang, Y., Andersen, M., Clewell, H., Plotzke, K. (2009). Harmonization of cyclic siloxanes PBPK model structure. Abstract 470. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 108, Number S-1.
23. Tan, Y., Peterson, S., Chang, D., Goldsmith, R., Tornero-Velez, R., Zhang, X., Knaak, J., Dary, C. (2010). The chemical landscape of existing PBPK models and its overlap with available open-access chemical databases. Abstract 882. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 114, Number S-1.
24. Goldsmith, R., Transue, T., Chang, D., Tan, Y., Tornero-Velez, R., Peterson, S., Johnson, J., Dary, C. (2010). Whole-body visualization of physiologically-relevant data of mice and men. Abstract 883. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 114, Number S-1.
25. Yoon, M., Kedderis, G., Tan, Y., Clewell, H. (2010). Using in vitro pharmacokinetic and pharmacodynamic data to refine the pharmacokinetic model for carbaryl in the rat. Abstract 895. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 114, Number S-1.
26. Loccisano, A., Tan, Y., Andersen, M., Clewell, H. (2010). Development of a rat gestation PBPK model for PFOA/PFOS. Abstract 1384. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 114, Number S-1.
27. Chang, D., Goldsmith, R., Transue, T., Tornero-Velez, R., Peterson, S., Tan, Y., Dary, C. (2010). Plasma-binding parameters in the embryonic compartment: an in silico screening tool for alpha-fetoprotein. Abstract 1386. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 114, Number S-1.
28. Goldsmith, R., Kenneke, J., Mazur, C., Chang, D., Tan, Y., Tornero-Velez, R., Dary, C., Ulrich, E. (2011). A show of hands for modern risk assessment: species-to-species extrapolations of stereoisomeric mixtures with provisional PBPK models. Abstract 721. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 120, Number S-1.
29. Tan, Y., Goldsmith, R., Daniel C., Zhang, X., Tornero-Velez, R., Johnson, J., Dary, C. (2011). The value of information from provisional PBPK models in support of biomonitoring: the case of atrazine. Abstract 1239. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 120, Number S-1.
30. Wambaugh, J., Tornero-Velez, R., McLanahan, E., Tan, Y., Setzer, W., Shah, I. (2011). Explicit pharmacokinetic modeling: tools for documentation, verification, and portability. Abstract 2693. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 120, Number S-1.

31. Goldsmith, R., Grulke, C., Transue, T., Chang, D., Tornero-Velez, r., Dary, c., Holm, K., Tan, Y., Egehg, P., Mitchell-Blackwood, J., Phillips, Vallerio, D. (2012). Personal chemical exposure informatics: creation of a consumer products chemical ingredient database. Abstract 293. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 126, Number S-1.
32. Tan, Y., Holm, K., Yoon, M., Young, B., Clewell, H., Tornero-Velez, R., Goldsmith, R., Chang, D., Grulke, C., Dary, C. (2012). Identifying the sources of uncertainty in the process of reconstructing exposures to carbaryl using exposure-to-dose modeling. Abstract 2440. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 126, Number S-1.
33. Holm, K., Tornero-Velez, R., Goldsmith, R., Chang, D., Grulke, C., Dary, C., Tan, Y. (2012) Exposure to organophosphate insecticides among children living along the US-Mexico Border. Abstract 2441. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 126, Number S-1.
34. Chang, D., Grulke, C., Goldsmith, R., Kenneke, J., Rawat, S., Marchitti, S., Mazur, C., Holm, K., Phillips, M., Tan, Y., Tornero-Velez, R., Dary, C. (2013) Selective criteria for determining catalytic competency in CYP3A4: a combined docking and pharmacophore study on triazole fungicide metabolism. Abstract 321. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 132, Number S-1.
35. Holm, K., McDougall, R., Yoon, M., Young, B., Clewell, H., Tornero-Velez, R., Goldsmith, M., Chang, D., Grulke, C., Phillips, M., Dary, C., Tan, Y. (2013) Identifying the sources of uncertainty in the process of reconstructing exposures to carbaryl using exposure-to-dose modeling. Abstract 799. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 132, Number S-1.
36. Phillips, M., Grulke, C., Yang, Y., Holm, K., Chang, D., Goldsmith, M., Tornero-Velez, R., Dary, C., Tan, Y. (2013) Conducting probabilistic reverse dosimetry calculations to estimate exposure concentrations from biomarker data – an example of perchlorate. Abstract 1253. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 132, Number S-1.
37. Tan, Y., Phillips, M., Sobus, J. (2013) Exploring challenges in reconstructing doses or estimating blood concentrations from urinary biomarker data using a pharmacokinetic model for perchlorate. Abstract 1907. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 132, Number S-1.
38. Lee, S., Tan, Y., Sobus, J., Phillips, M., Kim, S. (2014) Estimation of methylmercury intake doses in the South Korea population using a PBPK model. Abstract 2250c. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 138, Number S-1.
39. Phillips, M., Christensen, K., Blessinger, T., Lorber, M., Sobus, J., Tan, Y. (2014) Investigation of bias in epidemiologic associations using a PK model for DEHP. Abstract 96i. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 138, Number S-1.

40. Lu, J., Cai, Y., Tan, Y. (2015) Understanding the kinetics of amiodarone and its metabolite desethylamiodarone in rats using a physiologically based pharmacokinetic model. Abstract 734. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 144, Number S-1.
41. Phillips, M., Yoon, M., Young, B., Tan, Y. (2015) Biomarker utility analysis using an exposure-PBPK/PD model: a carbaryl case study. Abstract 738. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 144, Number S-1.
42. Edwards, S. and Tan, Y. (2015) Considering pharmacokinetics as the mechanistic bases to link chemical exposures to adverse outcome pathways. Abstract 852. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 144, Number S-1.
43. Tan, Y., Phillips, M., El-Masri, H., Edwards, S. (2015) An “ADME module” in the adverse outcome pathway knowledgebase. Abstract 857. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 144, Number S-1.
44. Leonard, J., Grulke, C., Goldsmith, M., Chang, D., Phillips, M., Tan, Y. (2015) Development of a conceptual module to investigate pharmacokinetic influences when evaluating chemicals in adverse outcome pathways. Abstract 2233. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 144, Number S-1.
45. Tan, Y., Leonard, J., Chang, D., El-Masri, H., Edwards, S., Goldsmith, R. (2015) A three-tiered approach for linking pharmacokinetic considerations to the adverse outcome pathway framework for chemical-specific risk assessment. SETAC Annual Meeting, November 1 – 4, 2015, Salt Lake City, UT.
46. Csiszar, S., Meyer, D., Egeghy, P., Price, P., Scanlon, K., Tan, Y., Thomas, K., Vallerio, D., Bare, J. (2015) Cross-pollinating LCA and chemical human exposure modeling to support decision making through improved sustainability analysis. SETAC Annual Meeting, November 1 – 4, 2015, Salt Lake City, UT.
47. Price, P. and Tan, Y. (2015) Exposure assessments and toxicology in the 21st Century. FutureTox III, November 19-20, 2015, Arlington, VA.
48. Tan, Y., Leonard, J., El-Masri, H., Edwards, S., Chang, D., and Goldsmith, R. (2015) A tiered approach for linking exposure and pharmacokinetics to adverse outcome pathways and *in vitro* data for high throughput risk assessment. FutureTox III, November 19-20, 2015, Arlington, VA.
49. Laessig, S., Szilagyi, M., Wang, R., Tan, Y. (2015) Investigating high throughput screening data for TSCA work plan chemicals. FutureTox III, November 19-20, 2015, Arlington, VA.
50. Lu, J., Goldsmith, M., Grulke, C., Chang, D., Leonard, J., Hypes, E., Fair, M., Tan, Y. (2016) A comprehensive physiologically based pharmacokinetic knowledgebase and web-based interface for rapid model ranking and querying. Abstract 2238. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 150, Number S-1.

51. Leonard, J., Tan, Y., Gilbert, M., Isaacs, K., El-Masri, H. (2016). Integrating High Throughput Exposure and Hazard Data Using a Physiologically Based Pharmacokinetic/pharmacodynamic Model for Thyroid Peroxidase Inhibitors. Abstract 2221. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 150, Number S-1.
52. Tan, Y., Leonard, J., Scholle, S., Winter, M., Key, P., Lu, J., Chang, D. (2016) Evaluating the Value of Augmenting In Vitro Hazard Assessment with Exposure and Pharmacokinetics Considerations for Chemical Prioritization. Abstract 2222. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 150, Number S-1.
53. Csiszar, S., Meyer, D., Dionisio, K., Egeghy, P., Isaacs, K., Price, P., Scanlon, K., Tan, Y., Thomas, K., Vallero, D., Bare, J. (2016) Case study combining LCA and high-throughput risk-based screening for chemicals in consumer products. American Center for Life Cycle Assessment, LCA XVI Conference, September 28 – 29, 2016, Charleston, SC.
54. Teeguarden, J., Tan, Y., Edwards, S., Egeghy, P., Leonard, J., Anderson, K., Corley, R., Harding, A., Kile, M., Simonich, S., Stone, D., Tanguay, R., Waters, K., Harper, S., Williams, D., Orme-Zavaleta, J., Bahadori, T. (2016). A conceptual framework to advance exposure science research and complete the source-to-outcome continuum for risk assessment. ISES Annual Meeting, October 9 – 13, 2016, Utrecht, The Netherlands.
55. Csiszar, S., Meyer, D., Dionisio, K., Egeghy, P., Isaacs, K., Price, P., Scanlon, K., Tan, Y., Thomas, K., Vallero, D., Bare, J. (2016) Integrating risk metrics into Life Cycle Assessment using high-throughput exposure modeling for consumer products: air freshener case study. SETAC Annual Meeting, November 6 – 10, 2016, Orlando, FL.
56. Tan, Y., Edwards, S., Teeguarden, J., Egeghy, P., Leonard, J. (2016). The Aggregate Exposure Pathway (AEP): A conceptual framework for advancing exposure science research and transforming risk assessment. SETAC Annual Meeting, November 6 – 10, 2016, Orlando, FL.
57. Paini, A., Tan, Y., Bessems, J., Desalegn, A., Dorne, J., Gosling, J., Heringa, M., Joossens, E., Klaric, M., Kramer, N., Loizou, G., Louise, J., Lumen, A., Madden, J., Patterson, E., Proenca, S., Punt, A., Setzer, W., Suci, N., Troutman, J., Yoon, M., Worth, A. (2017). Physiologically-based kinetic modelling in risk assessment – reaching a whole new level in regulatory decision-making, at a glance. National Centre for the Replacement, Refinement, & Reduction of Animals in Research Workshop: Applying exposure science to increase the utility of non-animal data in efficacy and safety testing, February 15 – 16, 2017, London, UK.
58. Leonard, J., Stevens, C., Mansouri, K., Chang, D., Tan, Y. (2017). Identifying metabolically active chemicals using a consensus quantitative structure activity model for estrogen receptor binding. Abstract 2932. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 156, Number S-1.

59. Moreau, M., Pendse, S., Phillips, M., Yoon, M., Campbell, J., Leonard, J., Smith, S., Tan, Y., Clewell, H. (2017). Case study on the application of the reverse dosimetry module in PLETHEM to estimate exposure of phthalates. Abstract 3178. *The Toxicologist – An Official Journal of the Society of Toxicology*, Volume 156, Number S-1.
60. Leonard, J.A., Stevens, C. Mansouri, K., Chang, D., Tan, Y. (2017) Identifying metabolically active chemicals using a consensus quantitative structure activity relationship model for estrogen receptor binding. OpenTox USA Annual Meeting, July 12-13, 2017, Durham, NC.
61. Leonard, J., Chang, D., El-Masri, H., Edwards, S., Stevens, C., Mansouri, K., Egeghy, P., Tan, Y. (2017) A tiered approach for integrating exposure and dosimetry with *in vitro* response data in the modern risk assessment paradigm. August 20-24, 2017, American Chemical Society Annual Meeting, Washington, DC.
62. Leonard, J.A., Chang, D., Tan, Y. (2017) Complementing *in vitro* hazard assessment with exposure and pharmacokinetics considerations for chemical prioritization. International Society of Exposure Science Annual Meeting, October 15-19, 2017, Durham, NC.
63. Tan (2018), A tiered approach to incorporate exposure and pharmacokinetics considerations in *in vitro* based safety assessment. Society of Toxicology Annual Meeting Continuing Education Course, March 11, 2018.
64. Leonard, J.A., El-Masri, H., Stevens, C., Mansouri, K., Tan, Y. (2018) Integrating exposure, pharmacokinetics, and dosimetry with *in vitro* dose-response data to evaluate chemical risk. *The Toxicologist*, Supplement to Toxicological Sciences, 162(1), Abstract 2477.
65. Worley, R., Leonard, J., Fisher, J., Tan, Y. (2018) Approaches for increasing acceptance of physiologically-based pharmacokinetic models in public health risk assessment. *The Toxicologist*, Supplement to Toxicological Sciences, 162(1), Abstract 3167.
66. Tan, Y. (2018) Incorporating toxicokinetic data and tools to support public health decision making. Eurotox 2018, September 2, 2018, Brussels, Belgium, *Toxicology Letter*, doi.org/10.1016/j.toxlet_2018.06.025.
67. Tan, Y., Leonard, J., Wambaugh, J., Isaacs, K., Villeneuve, D., LaLone, C., Edwards, S., Williams, A., Grulke, C. (2018) Free access platforms for integrating environmental chemical exposure and hazard information. Eurotox 2018, September 3, 2018, Brussels, Belgium, *Toxicology Letter*, doi.org/10.1016/j.toxlet.2018.06.1129.
68. Leonard, J., Nelms, M., Craig, E., Dobreniecki, S., Perron, M., Pope-Varsalone, H., Lowit, A., and Tan, Y. (2019) An integrated approach to evaluate common mechanisms of toxicity in pesticides to support cumulative risk assessment. *The Toxicologist*, Supplement to Toxicological Sciences, 168(1), Abstract 2762.

69. Tan, Y., Lowit, A., Embry, M. (2020) Applications of physiologically based pharmacokinetic (PBPK) modeling in regulatory risk assessment. *The Toxicologist, Supplement to Toxicological Sciences*, 174(1), Abstract 1539.
70. Pendse, S., Barton, H., Domoradzki, J., Bartels, M., Sayre, R., Brunner, R., Ingle, B., Tan, Y. (2021) Simulating the external-internal dose relationship for saturable pharmacokinetic processes. *The Toxicologist, Supplement to Toxicological Sciences*, 180(1), Abstract 2372.
71. Tan, Y. (2022) Leveraging Physiologically Based Pharmacokinetic (PBPK) Modeling for Refining Safety Assessment of Food, Drugs, and Chemicals under Data-Rich and Data-Poor Conditions. *The Toxicologist, Supplement to Toxicological Sciences*, 186(1), Abstract 1053.
72. Tan, Y. (2022) Applying Physiologically Based Pharmacokinetic (PBPK) Modeling to Design and Optimize Animal Toxicity Studies. *The Toxicologist, Supplement to Toxicological Sciences*, 186(1), Abstract 1277